title: Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial.
abstract: OBJECTIVE
  To compare the efficacy, adverse effects and acceptability of the three most common misoprostol regimens used with mifepristone for medical abortion.
  
  
  METHODS
  Randomised nonblinded trial.
  
  
  METHODS
  Three clinics associated with major research universities in Canada; two in major urban areas and one in a periurban area.
  
  
  METHODS
  Women of reproductive age.
  
  
  METHODS
  Consenting women presenting for abortion services with gestations less than 56 days and who met inclusion criteria were given 200 mg mifepristone orally and then randomised into three misoprostol study groups: (group I) 400 micrograms of oral misoprostol, (group II) 600 micrograms of oral misoprostol, and (group III) 800 micrograms of vaginal misoprostol. Misoprostol was self-administered at home 24-48 hours following mifepristone, and participants were instructed to take a second similar misoprostol dose at 24 hours after the initial dose if bleeding was less than a normal menstrual period.
  
  
  METHODS
  Successful abortion without surgery was 94.1%, with no significant differences across the three study groups (94.7% in group I, 93.4% in group II, and 94.3% in group III; P= 0.975).
  
  
  RESULTS
  Efficacy and adverse effects did not differ significantly across the three study groups. Pain increased significantly across the study and the gestational age groups and was associated with lower acceptability.
  
  
  CONCLUSIONS
  There appears to be a range of safe and effective options for early medical abortion with mifepristone including a choice between oral and vaginal administration of misoprostol.
authors.affiliation: Gynuity Health Projects, New York, NY, USA. caittespencer@yahoo.com
authors.forename: C
authors.initials: C
authors.lastname: Shannon
authors.forename: E
authors.initials: E
authors.lastname: Wiebe
authors.forename: F
authors.initials: F
authors.lastname: Jacot
authors.forename: E
authors.initials: E
authors.lastname: Guilbert
authors.forename: S
authors.initials: S
authors.lastname: Dunn
authors.forename: W R
authors.initials: WR
authors.lastname: Sheldon
authors.forename: B
authors.initials: B
authors.lastname: Winikoff
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced / Q000379:methods*; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D010146:Pain / Q000209:etiology; D017060:Patient Satisfaction; D011247:Pregnancy; D016896:Treatment Outcome; D014592:Uterine Hemorrhage / Q000209:etiology
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone